Century Therapeutics is in a technical breakout with a favorable 4.41 asymmetry ratio and substantial analyst-implied upside, but persistent cash burn keeps the quality score below the engine's floor, leaving the position dependent on continued clinical and financing execution.
Thesis pillars
- High Asymmetry Breakout Setup→Stable
- Large Analyst Upside Estimate→Stable
- Cash Burning Quality Below Floor→Stable
- +2 more pillars — see the Why tab for full reasoning
Century Therapeutics, Inc. (IPSC) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $2.08, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: CNTY-813 lead product candidate; Concentration risk — Supplier: FCDI license agreements.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement... Read more
Hold if already holding. Not a fresh buy at $2.08, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: CNTY-813 lead product candidate; Concentration risk — Supplier: FCDI license agreements. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $391M below $400M minimum. Not in investable universe. Score 5.4/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 19d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-07-25Recent Developments — Century Therapeutics, Inc.
Latest news
- NEWS Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower — benzinga Jun 30, 2026 neutral
Generated 2026-07-25T09:22:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineCNTY-813 lead product candidate10-K Item 1A: 'We are highly dependent on the success of our lead product candidate, CNTY-813, which we have initiated IND-enabling studies for, and our other product candidates'
- HIGHSupplierFCDI license agreements10-K Item 1A: 'If any of our license agreements with FCDI are terminated, we could lose our rights to key components enabling our iPSC-derived allogeneic cell therapy platforms.'
Material Events(8-K, last 90d)
- 2026-06-16Item 5.02LOWCSO Chad Cowan signed an Amended and Restated Employment Agreement June 15, 2026 to continue as CSO on a part-time basis at a reduced $296,150 salary. Not a departure; compensatory arrangement change only.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $2.08, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: CNTY-813 lead product candidate; Concentration risk — Supplier: FCDI license agreements. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $391M below $400M minimum. Not in investable universe. Target $4.04 (+94.2%), stop $2.02 (−3.0%), A.R:R 7.1:1. Score 5.4/10, moderate confidence.
Take-profit target: $4.04 (+91.4% upside). Target $4.04 (+94.2%), stop $2.02 (−3.0%), A.R:R 7.1:1. Stop-loss: $2.02.
Concentration risk — Pipeline: CNTY-813 lead product candidate; Concentration risk — Supplier: FCDI license agreements; Market cap $391M below $400M minimum.
Century Therapeutics, Inc. trades at a P/E of N/A (forward -4.7). TrendMatrix value score: 9.0/10. Verdict: Hold.
12 analysts cover IPSC with a consensus score of 4.0/5. Average price target: $5.
What does Century Therapeutics, Inc. do?Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the...
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.